A Phase 3 interventional study of Ixekizumab and Placebo in Axial Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 109 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-13.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 13 in phase 3, and was the 11th registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
CARE ARTHRITIS LTD. · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 200 across the 31 interventional studies, 50 across the 3 observational. Of the 21 that completed or were terminated, 17 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 34 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07836374University of MichiganRENEW Intervention for Axial Spondyloarthritis | 2027-03 |
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT07642622University of WashingtonPhysical Activity Through Health Technology in Axial Spondyloarthritis | 2027-04 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period. Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44.
Drug: Ixekizumab
Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period. Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44.
Drug: Ixekizumab
Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period. Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44.
Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).
Time frame: Week 16
Percentage of Participants Achieving an ASAS40 Response
ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).
Time frame: Week 52
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite index to assess disease activity in axial spondyloarthritis (axSpA). ASDAS parameters used with (C-reactive protein \[CRP\] as acute phase reactant) are: 1) Total back pain 2) Patient global 3) Peripheral pain/swelling, duration of morning stiffness 4) CRP in mg/L: ASDAScrp is calculated with the equation: 0.121 × total back pain + 0.110×patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least squares mean (LS Mean) was derived from mixed models repeated measure analysis (MMRM) with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite index to assess disease activity in axSpA. ASDAS parameters used (with CRP as acute phase reactant) are: 1 )Total back pain 2) Patient global 3) Peripheral pain/swelling 4) Duration of morning stiffness 5) CRP in mg/L: ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Number of Participants Without Clinically Meaningful Changes in Background Therapy
Number of participants without changes in background therapy while on originally randomized treatment.
Time frame: Baseline through Week 52
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
The SF-36 is a 36-item patient-administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The Physical Component Summary score ranges from 0 to 100; higher scores indicate better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
The medical outcomes study 36-item short-form health survey (SF-36) SF-36 PCS are summarized using the t-scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Percentage of Participants Achieving ASDAS Low Disease Activity
ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 16
Percentage of Participants Achieving ASDAS Low Disease Activity
ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 52
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
Both left and right SIJ are scored for bone marrow edema. Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LS Mean was derived from ANCOVA model with treatment, geographic region, screening MRI/CRP status and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in SPARCC Enthesitis Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. Participants were asked to rate the difficulty associated with 10 individual basic functional activities. Participant responded to each question using a NRS scale (range 0 to 10), with a higher score indicating worse functioning. The participant's final BASFI score is the mean of the 10 item scores with the minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Percentage of Participants Achieving ASDAS Inactive Disease
ASDAS is a composite index to assess disease activity in axSpA. ASDAS Inactive Disease is defined as a score of less than (\<)1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 52
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
High-sensitivity C-reactive protein (hs-CRP) was the measure of acute phase reactant and was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
Bath Ankylosing Spondylitis Metrology Index (BASMI) is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with axSpA: 1) Lateral spinal flexion 2) Tragus-to-wall distance 3) Lumbar flexion (modified Schrober) 4) Maximal intermalleolar distance, and 5) Cervical rotation. The BASMI includes these 5 measurements that were each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Chest Expansion
While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Occiput to Wall Distance
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed included costochondral 1 (right/left \[R/L\]), costochondral 7 (R/L), spinal iliaca anterior superior (R/L), crista iliaca (R/L), spina iliaca posterior (R/L), processus spinosus L5, and achilles tendon proximal insertion (R/L). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC) and Swollen Joint Count (SJC) Scores of 44 Joints
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body). The 46 joints are assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). Swollen joint count SJC was determined by examination of 44 joints (22 joints on each side of the participants body). The joints are classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which is multiplied by 44 to obtain SJC score. Score ranges from 0 (not swollen) to 44 (all joints swollen). LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status and baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Number of Participants With Anterior Uveitis
Number of participants with anterior uveitis. Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Baseline through Week 52
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in ASAS Health Index (ASAS HI)
ASAS-HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS Mean was derived MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS Mean was derived from using MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 52
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS Mean was derived from ANCOVA with treatment, geographic region, screening MRI/CRP status and baseline value.
Time frame: Baseline, Week 52
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, the higher the score, the greater the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).
Time frame: Baseline, Week 52
Number of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies
A treatment-emergent positive anti-drug antibody (TE-ADA+) participant will be defined as a 4-fold increase over a positive baseline antibody titer (Tier 3); or for a negative baseline titer, a participant with an increase from the baseline to a level of ≥ 1:10.
Time frame: Week 52
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss)
PK trough serum concentration samples were collected at steady state (Ctrough ss)
Time frame: Week 52
This study has 3 periods: Period 1 - Screening; Period 2 - A Double-Blind Treatment Period (Weeks 0 Up to 52); (Inadequate Responders \[IR\] Week 16-52) followed by a Follow-Up Period (Up to 24 Weeks after last visit)
| Milestone | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W (IxeQ4W) Double-Blind Period | Ixekizumab 80 mg Q2W (IxeQ2W) Double-Blind Period | PBO IR/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Treatment Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 105 | 96 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 104 | 96 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 97 | 95 | 98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W (IxeQ4W) Double-Blind Period | Ixekizumab 80 mg Q2W (IxeQ2W) Double-Blind Period | PBO IR/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Treatment Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 97 | 95 | 98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 34 | 52 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 63 | 43 | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Classified as inadequate responders (ir) | 62 | 40 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W (IxeQ4W) Double-Blind Period | Ixekizumab 80 mg Q2W (IxeQ2W) Double-Blind Period | PBO IR/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Treatment Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 62 | 40 | 42 | 0 | 0 | 0 | 0 |
| Initiated other biologic rescue | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 55 | 37 | 35 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 7 | 3 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 1 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W (IxeQ4W) Double-Blind Period | Ixekizumab 80 mg Q2W (IxeQ2W) Double-Blind Period | PBO IR/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q4W IR (Ixe80Q4WIR)/Ixe80Q2W-Open Label | Ixekizumab 80 mg Q2W IR (Ixe80Q2WIR)/Ixe80Q2W-Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Treatment Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 28 | 5 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 18 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 10 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 2 |
ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).
| percentage of participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response | 19.0 | 35.4 | 40.2 |
ASAS40 is defined as a greater than or equal to (≥)40% improvement and an absolute improvement from baseline of ≥2 units (ranges 0 to 10) in at least 3 of the 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), without any worsening in the remaining domain. 1) Patient Global: How active was your spondylitis during the last week? score ranges 0 (not active) to 10 (very active). 2) Spinal Pain: How much spinal pain due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3) Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Responses were captured using numeric rating scale (NRS) (ranges 0 to 10) with a higher score of worse function. 4) Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 (mean of intensity, duration of stiffness). Score ranges (0 (non) to 10 (very severe).
| percentage of participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving an ASAS40 Response | 13.3 | 30.2 | 31.4 |
ASDAS is a composite index to assess disease activity in axial spondyloarthritis (axSpA). ASDAS parameters used with (C-reactive protein \[CRP\] as acute phase reactant) are: 1) Total back pain 2) Patient global 3) Peripheral pain/swelling, duration of morning stiffness 4) CRP in mg/L: ASDAScrp is calculated with the equation: 0.121 × total back pain + 0.110×patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least squares mean (LS Mean) was derived from mixed models repeated measure analysis (MMRM) with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.58 ± 0.095 | -1.12 ± 0.097 | -1.26 ± 0.095 |
ASDAS is a composite index to assess disease activity in axSpA. ASDAS parameters used (with CRP as acute phase reactant) are: 1 )Total back pain 2) Patient global 3) Peripheral pain/swelling 4) Duration of morning stiffness 5) CRP in mg/L: ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in milligram/liter (mg/L), the range of other variables is from 0 to 10. Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.78 ± 0.136 | -1.39 ± 0.116 | -1.47 ± 0.116 |
Number of participants without changes in background therapy while on originally randomized treatment.
| Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Number of Participants Without Clinically Meaningful Changes in Background Therapy | 98 | 90 | 100 |
The SF-36 is a 36-item patient-administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The Physical Component Summary score ranges from 0 to 100; higher scores indicate better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | 5.2103 ± 0.7999 | 8.0612 ± 0.8129 | 7.9600 ± 0.8023 |
The medical outcomes study 36-item short-form health survey (SF-36) SF-36 PCS are summarized using the t-scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | 4.7210 ± 1.2459 | 8.9211 ± 1.0783 | 9.3291 ± 1.0810 |
ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| percentage of participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving ASDAS Low Disease Activity | 12.4 | 27.7 | 32.4 |
ASDAS is a composite index to assess disease activity in axSpA. ASDAS low disease activity is defined as a score of \<2.1. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| percentage of participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving ASDAS Low Disease Activity | 8.6 | 29.8 | 27.5 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -1.51 ± 0.216 | -2.18 ± 0.220 | -2.52 ± 0.217 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to axial spondyloarthritis (axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -1.76 ± 0.305 | -2.89 ± 0.266 | -3.04 ± 0.266 |
Both left and right SIJ are scored for bone marrow edema. Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LS Mean was derived from ANCOVA model with treatment, geographic region, screening MRI/CRP status and baseline value as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Sacroiliac Joint (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score | -0.31 ± 0.539 | -3.38 ± 0.549 | -4.52 ± 0.530 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value visit, baseline value-by-visit and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in SPARCC Enthesitis Score | -2.87 ± 0.447 | -2.99 ± 0.427 | -3.14 ± 0.407 |
BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. Participants were asked to rate the difficulty associated with 10 individual basic functional activities. Participant responded to each question using a NRS scale (range 0 to 10), with a higher score indicating worse functioning. The participant's final BASFI score is the mean of the 10 item scores with the minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | -1.57 ± 0.333 | -2.63 ± 0.292 | -2.75 ± 0.291 |
ASDAS is a composite index to assess disease activity in axSpA. ASDAS Inactive Disease is defined as a score of less than (\<)1.3. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| percentage of participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving ASDAS Inactive Disease | 2.9 | 13.5 | 10.8 |
High-sensitivity C-reactive protein (hs-CRP) was the measure of acute phase reactant and was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| milligram/liter (mg/L) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP) | -4.804 ± 2.0370 | -8.611 ± 2.0028 | -7.547 ± 1.9654 |
Bath Ankylosing Spondylitis Metrology Index (BASMI) is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with axSpA: 1) Lateral spinal flexion 2) Tragus-to-wall distance 3) Lumbar flexion (modified Schrober) 4) Maximal intermalleolar distance, and 5) Cervical rotation. The BASMI includes these 5 measurements that were each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) | -0.17 ± 0.112 | -0.56 ± 0.097 | -0.48 ± 0.097 |
While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| centimeter (cm) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Chest Expansion | 0.57 ± 0.253 | 0.62 ± 0.206 | 0.91 ± 0.209 |
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| cm | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Occiput to Wall Distance | 0.04 ± 0.312 | -0.42 ± 0.257 | -0.73 ± 0.259 |
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed included costochondral 1 (right/left \[R/L\]), costochondral 7 (R/L), spinal iliaca anterior superior (R/L), crista iliaca (R/L), spina iliaca posterior (R/L), processus spinosus L5, and achilles tendon proximal insertion (R/L). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) | -2.34 ± 0.361 | -3.21 ± 0.342 | -3.19 ± 0.336 |
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body). The 46 joints are assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). Swollen joint count SJC was determined by examination of 44 joints (22 joints on each side of the participants body). The joints are classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which is multiplied by 44 to obtain SJC score. Score ranges from 0 (not swollen) to 44 (all joints swollen). LS mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status and baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| joint counts | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| TJC | -0.59 ± 1.039 | -2.38 ± 0.993 | -4.12 ± 0.916 |
| SJC | -3.66 ± 0.261 | -4.63 ± 0.237 | -4.41 ± 0.228 |
Number of participants with anterior uveitis. Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Number of Participants With Anterior Uveitis | 2 | 1 | 2 |
The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LS Mean was derived from MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score | -2.1 ± 0.38 | -2.6 ± 0.32 | -2.7 ± 0.32 |
ASAS-HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS Mean was derived MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in ASAS Health Index (ASAS HI) | -2.57 ± 0.455 | -3.16 ± 0.395 | -3.54 ± 0.396 |
Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS Mean was derived from using MMRM with treatment, geographic region, screening MRI/CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| units on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ) | -2.9 ± 0.63 | -3.6 ± 0.52 | -3.6 ± 0.53 |
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS Mean was derived from ANCOVA with treatment, geographic region, screening MRI/CRP status and baseline value.
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Overall Impairment Score | -13.20 ± 3.386 | -26.96 ± 3.439 | -19.49 ± 3.221 |
| Percentage of absenteeism | -3.11 ± 2.215 | -9.01 ± 2.257 | -7.26 ± 2.151 |
| Percentage of presenteeism | -12.40 ± 3.200 | -26.01 ± 3.245 | -18.61 ± 3.047 |
| Percentage of impairment in activities | -14.42 ± 2.584 | -25.05 ± 2.617 | -24.41 ± 2.567 |
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI). For NSAID equivalent scoring system, range is from 0 to 100, the higher the score, the greater the NSAID intake. ASAS-NSAID score= (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days).
| score on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score | -8.89 ± 29.986 | -7.91 ± 34.257 | -5.33 ± 20.935 |
A treatment-emergent positive anti-drug antibody (TE-ADA+) participant will be defined as a 4-fold increase over a positive baseline antibody titer (Tier 3); or for a negative baseline titer, a participant with an increase from the baseline to a level of ≥ 1:10.
| Participants | Ixe80Q2W-Q2W | Ixe80Q4W-Q4W | PBO-Ixe80Q2W | Ixe80Q4W-Q2W |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent (TE) Anti-Ixekizumab Antibodies | 14 | 5 | 8 | 2 |
PK trough serum concentration samples were collected at steady state (Ctrough ss)
| microgram/milliliter (μg/mL) | IxeQ2W (80S)/IxeQ2W | IxeQ2W (80S)/IxeQ2W Open Label | IxeQ2W (160S)/IxeQ2W | IxeQ2W (160s)/IxeQ2W Open Label | IxeQ4W (80S) IxeQ4W | IxeQ4W (80S)/IxeQ2W Open Label | IxeQ4W(160S)/IxeQ4W | IxeQ4W (160S) IxeQ2W Open Label | PBO/IxeQ2W Open Label |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough ss) | 7.88 ± 73 | 9.56 ± 60 | 10.3 ± 61 | 10.4 ± 72 | 2.88 ± 49 | 6.45 ± 124 | 3.54 ± 79 | 11.5 ± 53 | 9.25 ± 66 |
Collected over Up to 76 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Double-Blind Period | 0/104 (0%) | 1/104 (1%) | 31/104 (29.8%) |
| Ixekizumab 80 mg Q4W Double-Blind Period | 0/96 (0%) | 2/96 (2.1%) | 43/96 (44.8%) |
| Ixekizumab 80 mg Q2W Double-Blind Period | 0/102 (0%) | 1/102 (1%) | 47/102 (46.1%) |
| PBO IR/IxeQ2W Open Label | 0/42 (0%) | 1/42 (2.4%) | 13/42 (31%) |
| Ixe80Q4WIR/Ixe80Q2W Open Label | 0/40 (0%) | 0/40 (0%) | 15/40 (37.5%) |
| Ixe80Q2WIR/Ixe80Q2W Open Label | 0/62 (0%) | 2/62 (3.2%) | 26/62 (41.9%) |
| Other Biologic Open Label | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Placebo Post Treatment Follow-Up Period | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | 0/28 (0%) | 1/28 (3.6%) | 1/28 (3.6%) |
| Other Biologic Post Treatment Follow-Up Period | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W Double-Blind Period | Ixekizumab 80 mg Q2W Double-Blind Period | PBO IR/IxeQ2W Open Label | Ixe80Q4WIR/Ixe80Q2W Open Label | Ixe80Q2WIR/Ixe80Q2W Open Label | Other Biologic Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Axial spondyloarthritisMusculoskeletal and connective tissue disorders | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 1/28 | 0/5 |
| Focal dyscognitive seizuresNervous system disorders | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 1/28 | 0/5 |
| Somatic symptom disorderPsychiatric disorders | 0/104 | 0/96 | 0/102 | 1/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| SinusitisInfections and infestations | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 1/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 1/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 1/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Abdominal painGastrointestinal disorders | 0/104 | 1/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| ErysipelasInfections and infestations | 0/104 | 1/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Major depressionPsychiatric disorders | 0/104 | 0/96 | 1/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Anaphylactoid reactionImmune system disorders | 1/104 | 0/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Event | Placebo Double-Blind Period | Ixekizumab 80 mg Q4W Double-Blind Period | Ixekizumab 80 mg Q2W Double-Blind Period | PBO IR/IxeQ2W Open Label | Ixe80Q4WIR/Ixe80Q2W Open Label | Ixe80Q2WIR/Ixe80Q2W Open Label | Other Biologic Open Label | Placebo Post Treatment Follow-Up Period | Ixekizumab 80 mg Q4W Post Treatment Follow-Up Period | Ixekizumab 80 mg Q2W Post Treatment Follow-Up Period | Other Biologic Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 2/104 | 0/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 1/3 | 0/5 | 0/28 | 0/5 |
| PharyngitisInfections and infestations | 4/104 | 4/96 | 2/102 | 2/42 | 3/40 | 3/62 | 0/5 | 1/3 | 0/5 | 0/28 | 0/5 |
| IritisEye disorders | 0/104 | 0/96 | 0/102 | 0/42 | 0/40 | 0/62 | 0/5 | 0/3 | 1/5 | 0/28 | 0/5 |
| NasopharyngitisInfections and infestations | 8/104 | 18/96 | 16/102 | 2/42 | 7/40 | 6/62 | 1/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 4/104 | 4/96 | 6/102 | 2/42 | 3/40 | 4/62 | 1/5 | 0/3 | 0/5 | 1/28 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 2/104 | 3/96 | 2/102 | 0/42 | 0/40 | 0/62 | 1/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/104 | 1/96 | 5/102 | 1/42 | 0/40 | 0/62 | 1/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Injection site reactionGeneral disorders | 4/104 | 11/96 | 17/102 | 3/42 | 3/40 | 11/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| NauseaGastrointestinal disorders | 1/104 | 1/96 | 1/102 | 4/42 | 2/40 | 0/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
| Injection site erythemaGeneral disorders | 1/104 | 3/96 | 4/102 | 2/42 | 0/40 | 5/62 | 0/5 | 0/3 | 0/5 | 0/28 | 0/5 |
All randomized participants.
| Age, Continuous(years) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 39.9 ± 12.36 | 40.9 ± 14.47 | 40.0 ± 12.01 | 40.3 ± 12.92 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Female | 61 | 46 | 53 | 160 |
| Male | 44 | 50 | 49 | 143 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 24 | 31 | 80 |
| Not Hispanic or Latino | 68 | 57 | 63 | 188 |
| Unknown or Not Reported | 12 | 15 | 8 | 35 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 8 | 2 | 3 | 13 |
| Asian | 17 | 13 | 11 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 76 | 80 | 83 | 239 |
| More than one race | 3 | 1 | 5 | 9 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Argentina | 8 | 6 | 9 | 23 |
| Romania | 5 | 1 | 4 | 10 |
| United States | 10 | 9 | 9 | 28 |
| Czechia | 15 | 16 | 13 | 44 |
| Japan | 6 | 5 | 5 | 16 |
| Russia | 12 | 7 | 8 | 27 |
| Canada | 1 | 3 | 2 | 6 |
| Austria | 0 | 1 | 2 | 3 |
| South Korea | 9 | 7 | 6 | 22 |
| Netherlands | 0 | 0 | 1 | 1 |
| Finland | 4 | 3 | 3 | 10 |
| Brazil | 0 | 1 | 2 | 3 |
| Poland | 19 | 18 | 20 | 57 |
| Mexico | 14 | 13 | 15 | 42 |
| Germany | 2 | 6 | 3 | 11 |
Showing the first 100 of 109 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2016 to primary completion in Mar 2019, 30 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab